Gilead Speeds Manufacture of Experimental COVID-19 Drug, Doesn’t Plan to Charge

Gilead Speeds Manufacture of Experimental COVID-19 Drug, Doesn’t Plan to Charge

Source: 
BioSpace
snippet: 

One of the promising experimental drugs being tested to treat COVID-19, the disease caused by the novel coronavirus SARS-Cov2-, is Gilead Sciences’ remdesivir. The company had decided to accelerate its production of the drug based on overwhelming demand. The company indicated it currently has 1.5 million individual doses available, which could potentially be used to treat 140,000 patients. It does not plan to charge for the drug at this time.